Enzymotec (Migdal HaEmeq, Israel) and Mercola.com have co-launched Krill-IQ, a product containing krill-derived phosphatidylserine (PS) and an omega-3/astaxanthin complex of krill and alpha-glycerylphosphorylcholine (Alpha-GPC).
Enzymotec (Migdal HaEmeq, Israel) and Mercola.com have co-launched Krill-IQ, a product containing krill-derived phosphatidylserine (PS) and an omega-3/astaxanthin complex of krill and alpha-glycerylphosphorylcholine (Alpha-GPC).
All ingredients are supplied by Enzymotec.
Enzymotec explains the potential health benefits of Krill-IQ below:
Mercola’s Krill-IQ brings together four important elements: nutrients to support brain cell and nerve cell function, nutrients to help protect against long-term effects of oxidation and inflammation, and nutrients that may provide both short-term and long-term effects with solid scientific rationale-for healthy brain functions.
Enzymotec has also launched Sharp-PS Green, a soy allergen-free PS ingredient.
Recent animal study finds that Lysoveta may help reduce neonatal brain injury
July 17th 2024A recent animal study found that lysophosphatidylcholine (LPC)-bound omega-3 long-chain polyunsaturated fatty acids (LCPUFAs), marketed as Lysoveta by Aker BioMarine, protected against neonatal hypoxic-ischemic (HI) brain injury in mice.
Krill oil supplementation raises Omega-3 Index of Lupus patients in recent study
July 16th 2024The study was conducted at 20 research centers in the United States by Aker BioMarine and the Lupus Clinical Investigators Network with oversight by Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.